What Is Wegovy? A Plain-English Definition, How It Works, and What It Treats

Key Takeaways

• Wegovy is a once-weekly injectable semaglutide medication FDA-approved for chronic weight management in adults and adolescents (age 12+) with obesity or overweight plus a comorbidity.
• It's manufactured by Novo Nordisk and contains the same active ingredient as Ozempic and Rybelsus, but at a higher dose (2.4 mg) and with weight management as its primary FDA indication.
• In the STEP 1 trial, adults on Wegovy lost 14.9% of body weight on average over 68 weeks (Wilding et al., NEJM 2021).
• In March 2024, the FDA approved Wegovy for cardiovascular risk reduction in adults with obesity and established cardiovascular disease (SELECT trial).
• Wegovy's list price is $1,349.02 per month in 2026; with the manufacturer savings card, eligible commercially insured patients pay as little as $0 to $25 per month.

Direct answer (40-60 words)

Wegovy is a once-weekly injectable prescription medication containing semaglutide, made by Novo Nordisk, FDA-approved for chronic weight management in adults and adolescents 12 and older. It works by mimicking the GLP-1 hormone to reduce appetite, slow digestion, and lower body weight. The 2024 FDA expansion added cardiovascular risk reduction as an indication.

Table of contents

1. The 30-second answer
2. The chemistry: what semaglutide is
3. What Wegovy is FDA-approved to treat
4. How Wegovy works in your body
5. Wegovy dosing schedule
6. Side effects and warnings
7. How Wegovy differs from Ozempic, Rybelsus, and Zepbound
8. Wegovy in adolescents (age 12 and up)
9. Cost and insurance coverage
10. Compounded semaglutide as an alternative
11. FAQ
12. Sources
13. Footer disclaimers

The chemistry: what semaglutide is

Semaglutide is the active ingredient in Wegovy. It's a synthetic peptide (a small protein) designed to mimic GLP-1, a hormone your gut releases naturally when you eat.

Native GLP-1 has a half-life of about 2 minutes; your body breaks it down quickly via DPP-4. Semaglutide was engineered with three modifications to extend that half-life to about 7 days:

1. A substituted amino acid at position 8 (alpha-aminoisobutyric acid replaces alanine), which makes the peptide resistant to DPP-4 cleavage.
2. A fatty acid chain attached at position 26, which lets the molecule bind reversibly to albumin in the blood. Albumin acts as a slow-release reservoir.
3. An additional amino acid substitution at position 34 to prevent unintended fatty acid binding.

The result is a peptide that activates the same GLP-1 receptors as the natural hormone but lasts a week per dose instead of minutes.

Wegovy and Ozempic both contain semaglutide. The difference is dose and indication: Wegovy is dosed up to 2.4 mg weekly for chronic weight management; Ozempic is dosed up to 2 mg weekly for type 2 diabetes.

What Wegovy is FDA-approved to treat

Wegovy has three FDA-approved indications as of 2026.

1. Chronic weight management in adults (June 2021). Approved as an adjunct to a reduced-calorie diet and increased physical activity for adults with:

• BMI ≥30 (obesity), or
• BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease)

Approval was based on the STEP 1 trial (Wilding et al., NEJM 2021), which showed adults on 2.4 mg weekly semaglutide lost an average of 14.9% of body weight at 68 weeks compared to 2.4% on placebo, both groups receiving lifestyle intervention.

2. Chronic weight management in adolescents 12 and older (December 2022). Approved for adolescents with BMI at or above the 95th percentile (obesity) based on age and sex. Approval was based on the STEP TEENS trial (Weghuber et al., NEJM 2022), which showed 16.1% mean BMI reduction at 68 weeks.

3. Cardiovascular risk reduction (March 2024). Approved for adults with established cardiovascular disease and obesity (BMI ≥27) to reduce the risk of major adverse cardiovascular events. Approval was based on the SELECT trial (Lincoff et al., NEJM 2023), which showed a 20% relative risk reduction in cardiovascular death, non-fatal MI, or non-fatal stroke at 39.8 months of follow-up.

Wegovy is not FDA-approved for type 2 diabetes management. Ozempic, which contains the same drug at lower doses, holds that indication.

How Wegovy works in your body

Semaglutide activates GLP-1 receptors throughout the body. Four physiological effects follow.

Effect 1: Central appetite regulation. GLP-1 receptors in the hypothalamus and brainstem regulate hunger and satiety signals. Activation reduces appetite, food cravings, and food preoccupation. This is the most clinically important mechanism for weight loss.

Effect 2: Slowed gastric emptying. Food stays in the stomach longer (about 65% longer at maintenance dose, per Davies et al., Diabetes Care 2023). This delays carbohydrate absorption and increases the duration of fullness after meals.

Effect 3: Glucose-dependent insulin release. The pancreas releases more insulin in response to elevated blood sugar. This contributes to better glycemic control in patients with insulin resistance, even when type 2 diabetes is not the primary indication.

Effect 4: Glucagon suppression. Glucagon (which tells the liver to release sugar) is reduced after meals, lowering post-meal blood sugar spikes.

Together, these effects reduce caloric intake, improve metabolic markers, and produce sustained weight loss in most patients. The brain mechanism is particularly notable: many patients report a quieting of "food noise" (intrusive thoughts about food) within 4 to 8 weeks of starting Wegovy.

Wegovy dosing schedule

Wegovy follows a 5-step titration over 16 weeks to reach the maintenance dose, designed to minimize gastrointestinal side effects.

The maintenance dose is 2.4 mg weekly. Patients who cannot tolerate the next step can stay at the current dose for an additional 4 weeks before retrying.

The drug is injected subcutaneously into the abdomen, thigh, or upper arm using a single-dose pre-filled pen. The needle is hidden inside the auto-injector. Each pen delivers one dose; patients use 4 pens per month.

For most patients, treatment is indefinite. The STEP 4 trial (Rubino et al., JAMA 2021) showed that participants who stopped Wegovy after 20 weeks regained two-thirds of their lost weight within the next 48 weeks, while those who continued maintained or increased their loss.

Side effects and warnings

The most common Wegovy side effects from the STEP 1 trial:

Most GI side effects are mild to moderate and improve with time. They are most common during dose escalation and typically taper after 4 to 8 weeks at a stable dose.

Serious warnings (boxed warning):

• Risk of thyroid C-cell tumors (medullary thyroid carcinoma). Wegovy is contraindicated in patients with personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).

Other important risks:

• Pancreatitis (acute, sometimes severe). Stop Wegovy if pancreatitis is suspected.
• Gallbladder disease (cholelithiasis, cholecystitis). Risk of gallstones increases with rapid weight loss.
• Acute kidney injury, often related to dehydration from severe nausea/vomiting.
• Hypoglycemia, especially if combined with insulin or sulfonylureas.
• Diabetic retinopathy complications (in patients with type 2 diabetes).
• Hypersensitivity reactions, including rare anaphylaxis and angioedema.
• Suicidal behavior and ideation: post-marketing reports prompted FDA labeling updates. Ongoing monitoring is recommended.

For more on managing side effects, see Wegovy side effects.

How Wegovy differs from Ozempic, Rybelsus, and Zepbound

Wegovy and Ozempic share the same molecule. The clinical difference is the dose: Wegovy reaches 2.4 mg weekly versus Ozempic's 2 mg ceiling. The 0.4 mg difference produces meaningfully more weight loss in trials but also more GI side effects.

Zepbound (tirzepatide) is a different molecule that activates both GLP-1 and GIP receptors. In the head-to-head SURMOUNT-5 trial, tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide at 72 weeks (Aronne et al., NEJM 2024).

Wegovy in adolescents (age 12 and up)

Wegovy is one of two GLP-1 drugs FDA-approved for adolescent obesity (the other is Saxenda/liraglutide). The pediatric indication is for adolescents 12 and older with BMI at or above the 95th percentile.

The STEP TEENS trial (Weghuber et al., NEJM 2022) enrolled 201 adolescents (mean age 15.4 years, mean BMI 37.0). Participants on 2.4 mg semaglutide weekly plus lifestyle intervention had a mean BMI change of -16.1% at week 68 versus +0.6% in the placebo+lifestyle group. About 45% of treated participants achieved at least 20% BMI reduction.

Side effects in adolescents were similar in pattern to adults, though gallbladder disease and severe nausea were notable. Long-term safety data in adolescents continue to accumulate.

For adolescents, Wegovy is typically prescribed only after a structured pediatric weight management program has been attempted, and only with a prescriber experienced in pediatric obesity care.

Cost and insurance coverage

Wegovy's 2026 list price is $1,349.02 per month at retail pharmacies (Novo Nordisk press release, 2024). Real costs vary widely based on insurance status.

With commercial insurance that covers Wegovy: The Wegovy Savings Card reduces eligible copays to as little as $0 per month (with insurance coverage) or $499 per month (with insurance that does not cover Wegovy). Patients without commercial insurance are not eligible for the savings card.

Without insurance: Cash price runs $1,300 to $1,400 per month. NovoCare offers a 4-pen supply for $499 to commercially insured patients without coverage.

Medicare: Medicare Part D does not cover Wegovy for weight loss. Coverage applies only when prescribed for cardiovascular risk reduction in adults with established CVD and obesity (added in 2024 after the FDA's expanded indication). Sleep apnea coverage applies to tirzepatide, not Wegovy.

Medicaid: Coverage varies by state. Fewer than 20 state Medicaid programs cover Wegovy for weight management. Most cover Wegovy for the cardiovascular indication where applicable.

For a deeper cost breakdown, see Wegovy savings card.

Compounded semaglutide as an alternative

Compounded semaglutide is the most common alternative to Wegovy for patients without coverage.

Pricing:

• FormBlends compounded semaglutide: $179 to $279 per month
• Other major telehealth platforms: $199 to $499 per month

Important compliance notes:

• Compounded semaglutide is not FDA-approved
• It is prepared by a state-licensed compounding pharmacy in response to an individual prescription
• It has not undergone the FDA review process that Wegovy has completed
• It is not interchangeable with Wegovy

When compounded makes sense: Insurance does not cover Wegovy, the savings card price is still unaffordable, and a licensed clinician determines compounded therapy is medically appropriate.

When brand-name Wegovy makes sense: You qualify for the $0 to $25 Savings Card price with covered commercial insurance, you need the FDA-approved auto-injector convenience, or you strongly prefer FDA-approved medications.

FAQ

What is Wegovy used for? Wegovy is FDA-approved for chronic weight management in adults and adolescents (12+) with obesity or overweight plus a comorbidity. It's also approved for cardiovascular risk reduction in adults with established cardiovascular disease and obesity. It is not approved for type 2 diabetes management.

Is Wegovy the same as Ozempic? Wegovy and Ozempic both contain semaglutide, the same active ingredient, made by the same manufacturer (Novo Nordisk). The difference is dose (Wegovy goes up to 2.4 mg weekly, Ozempic up to 2 mg) and indication (Wegovy for weight loss, Ozempic for type 2 diabetes). They are not interchangeable.

How much weight do you lose on Wegovy? In the STEP 1 trial (Wilding et al., NEJM 2021), adults lost an average of 14.9% of body weight at 68 weeks on 2.4 mg Wegovy weekly. Individual results vary widely. About one-third of trial participants lost at least 20% of body weight; another third lost 10% to 20%.

How does Wegovy work? Wegovy mimics GLP-1, a gut hormone that signals fullness. It reduces appetite by acting on brain receptors, slows stomach emptying so food stays longer, and improves blood sugar regulation. Together, these effects lead to lower caloric intake and sustained weight loss over months.

What are the most common Wegovy side effects? Nausea (44%), diarrhea (32%), vomiting (25%), constipation (24%), and abdominal pain (20%) per the STEP 1 trial. Most GI side effects are mild to moderate and improve over 4 to 8 weeks. Serious risks include pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumors.

How long do you stay on Wegovy? Wegovy is intended for long-term use. The STEP 4 trial showed patients who stopped after 20 weeks regained two-thirds of their lost weight in the next 48 weeks. Most clinicians treat obesity as a chronic condition requiring continuous medication, similar to hypertension or diabetes.

Can I take Wegovy if I don't have diabetes? Yes. Wegovy is FDA-approved for chronic weight management based on BMI criteria (≥30, or ≥27 with comorbidity), regardless of diabetes status. Many patients without diabetes use Wegovy. Insurance coverage often requires documentation of obesity-related comorbidities.

How much does Wegovy cost? List price is $1,349.02 per month in 2026. With the Wegovy Savings Card and commercial insurance coverage, eligible patients pay as little as $0 to $25 per month. Without coverage, NovoCare offers a 4-pen supply for $499 to commercially insured patients.

Does Medicare cover Wegovy? Medicare Part D does not cover Wegovy for weight loss. As of 2024, Medicare covers Wegovy for cardiovascular risk reduction in adults with obesity and established CVD. The weight loss exclusion under the Medicare Modernization Act still applies to non-CVD indications.

Can teenagers take Wegovy? Yes. Wegovy is FDA-approved for adolescents 12 and older with BMI at or above the 95th percentile. The STEP TEENS trial showed 16.1% mean BMI reduction at 68 weeks. Adolescent use should be supervised by a prescriber experienced in pediatric obesity care.

What if I miss a Wegovy dose? If you miss a dose and the next dose is more than 48 hours away, take the missed dose as soon as possible. If less than 48 hours remain until the next dose, skip the missed dose and continue the regular schedule. Do not double up doses.

Is compounded semaglutide the same as Wegovy? No. Compounded semaglutide and Wegovy both contain semaglutide as the active ingredient, but compounded products are not FDA-approved. They are prepared by state-licensed compounding pharmacies in response to individual prescriptions. They have not undergone the same review process as Wegovy and are not interchangeable.

Sources

1. Novo Nordisk. Wegovy (semaglutide) prescribing information, revised 2024.
2. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
3. Weghuber D, et al. Once-weekly semaglutide in adolescents with obesity (STEP TEENS). N Engl J Med. 2022;387:2245-2257.
4. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
5. Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325:1414-1425.
6. Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2024.
7. Davies M, et al. Semaglutide effects on gastric emptying and appetite. Diabetes Care. 2023.
8. U.S. Food and Drug Administration. FDA approves Wegovy for cardiovascular risk reduction. FDA Press Release, March 8, 2024.
9. U.S. Food and Drug Administration. FDA approves Wegovy for adolescents 12+ with obesity. FDA Press Release, December 23, 2022.
10. Centers for Medicare & Medicaid Services. CMS Memo: Coverage of GLP-1 receptor agonists. CMS, 2024.
11. Novo Nordisk press release. NovoCare Pharmacy and Wegovy Savings Card updates. 2024.
12. United States Pharmacopeia. USP General Chapter <797>: Pharmaceutical Compounding-Sterile Preparations. USP, 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Rybelsus, Saxenda, and NovoCare are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.